Go Deep
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 8,607 | -1.1 | 23.32 | 1.83 | 93.62 |
| Oct 2026 | 7,869 | -1.2 | 24.60 | 1.83 | 98.76 |
| Oct 2026 | 8,551 | -1.1 | 23.42 | 1.83 | 93.78 |
| Oct 2026 | 8,416 | -1.1 | 23.66 | 1.83 | 94.82 |
| Oct 2026 | 8,279 | -1.1 | 23.89 | 1.83 | 95.76 |
| Oct 2026 | 11,213 | -0.9 | 18.81 | 1.83 | 75.22 |
| Oct 2026 | 10,618 | -0.9 | 19.84 | 1.83 | 79.18 |
Inovio Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -6,012,458.0 | -19,682,798.0 | 3,764,880.0 | -45,496,672.0 |
| EPS | -0.1 | -0.3 | — | -0.9 |
Inovio Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 65,343.0 | 217,756.0 | 832,010.0 | 10,262,268.0 | — |
| Net Profit | -84,945,901.0 | -107,254,126.0 | -135,117,352.0 | -279,818,065.0 | — |
| EPS | -1.8 | -4.0 | -6.1 | -14.0 | — |
Inovio Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 74,310,035.0 | 113,197,206.0 | 170,951,423.0 | 348,533,302.0 | — |
| Total Liabilities | 50,213,759.0 | 44,693,411.0 | 53,602,294.0 | 126,170,546.0 | — |
| Total Equity | 24,096,276.0 | 68,503,795.0 | 117,349,129.0 | 222,362,756.0 | — |
Owes vs Owns
Inovio Pharmaceuticals, Inc. owed $0.91 for every $1 it owned in Jun 2026, up from $0.36 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.91× | 0.68× | 0.39× | 0.31× | 0.36× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Inovio Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 78.7%Fixed assets (tangible) 12.2%Long-term investments 2.8%Other assets 6.2%
How it's funded — Dec 2025
Short-term debt 3.8%Long-term debt 8.8%Payables 3.5%Other liabilities 51.4%Shareholders' equity 32.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 58.5 | 94.1 | 145.3 | 253.0 |
| Receivables | 0.0 | 1.2 | 2.4 | 11.7 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 9.1 | 11.8 | 14.5 | 18.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 12.6 |
| Long-term investments | 2.1 | 1.6 | 2.8 | 2.0 |
| Other assets | 4.6 | 4.5 | 6.0 | 51.2 |
| Liabilities & equity | ||||
| Short-term debt | 2.8 | 2.5 | 16.8 | 2.8 |
| Long-term debt | 6.5 | 9.4 | 11.0 | 16.6 |
| Payables | 2.6 | 6.4 | 4.6 | 21.1 |
| Other liabilities | 38.2 | 26.4 | 21.2 | 85.7 |
| Shareholders' equity | 24.1 | 68.5 | 117.3 | 222.4 |
| Net tangible assets | 24.1 | 68.5 | 117.3 | 209.7 |
Inovio Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -88,629,430.0 | -104,076,553.0 | -124,365,551.0 | -216,215,421.0 | — |
| Investing Activities | 14,039,357.0 | 104,071,039.0 | 87,355,875.0 | 109,585,856.0 | — |
| Financing Activities | 53,050,095.0 | 51,475,546.0 | 4,995,099.0 | 81,840,702.0 | — |